Windward Bio Debuts on Nasdaq, Shares Jump 68% at Close
Clinical-stage biotech Windward Bio priced its IPO at $17 and closed at $28.50 on its first trading day on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, under the ticker symbol WWB, the Shanghai-based firm announced Thursday.
The company priced its initial public offering at $17.00 per share, but investor demand pushed the stock significantly higher on the first day of trading. Shares closed at $28.50, representing a gain of roughly 68 percent from the IPO price — a strong opening performance by any standard measure in the current biotech market environment.
Read more NYSE Pre-Market Update Highlights HLTH USA 2026 Healthcare Event →
Windward Bio focuses on immunology, positioning itself within one of the more competitive and capital-intensive segments of the biotechnology sector. The company is listed as a portfolio company of Qiming Venture Partners, a prominent venture capital firm with deep roots in Asian technology and life sciences investment.
The listing marks a notable milestone for the company as it transitions from a privately funded, clinical-stage operation to a publicly accountable entity with access to capital markets. The proceeds from the offering are expected to support the advancement of its clinical programs, though specific pipeline details were not disclosed in the announcement.
Continue reading at All Financial Services & Investing.